Newron Pharmaceuticals SpA (CHIX:NWRNZ) FFO


CHIX:NWRNZ Newron Pharmaceuticals SpA CHIX:NWRNZ
48 GF Score
Price CHF12.62
GF Value CHF12.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:NWRNZ
48GF Score
Newron Pharmaceuticals SpA CHIX:NWRNZ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (CHIX:NWRNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.62 is trading 2.1% below its estimated GF Value™ of CHF12.89. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for CHIX:NWRNZ:

  • FFO:
  • GF Value™: CHF12.89 vs. price of CHF12.62 (2.1% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the CHIX:NWRNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
48GF Score

Get the complete analysis for CHIX:NWRNZ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.62
Price
CHF12.89
GF Value